Table 4 Multivariable analysis for late DR in the low risk group by CTS5.

From: Validation of Clinical Treatment Score post-5 years (CTS5) risk stratification in premenopausal breast cancer patients and Ki-67 labelling index

 

Low risk patients

(N = 480)

HR (95% CI)

P value

Age at diagnosis

0.95 (0.87–1.03)

.163

Tumor size (mm)

< 10

Ref

 

10–20

1.95 (0.38–10.15)

.426

> 20

2.95 (0.20–42.60)

.428

Pathologic nodal status

Negative

Ref

 

Positive

1.48 (0.15–14.84)

.741

Histologic grade

Low/Intermediate

Ref

 

High

0.89 (0.11–7.55)

.915

Chemotherapy

Not administered

Ref

 

Administered

0.58 (0.14–2.45)

.461

Ki-67 LI

≤ 20%

Ref

 

> 20%

5.23 (1.46–18.74)

.011

  1. HRs of PR, HER2 could not be estimated.
  2. CTS5, Clinical Treatment Score post-5 years; DR, distant recurrence; HER2, human epidermal growth factor receptor 2; HR, hazard ratio; LI, labelling index.
Back to article page